| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory.
|
J Neurosci
|
2005
|
12.85
|
|
2
|
Consensus nomenclature for in vivo imaging of reversibly binding radioligands.
|
J Cereb Blood Flow Metab
|
2007
|
11.79
|
|
3
|
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.
|
Ann Neurol
|
2006
|
11.23
|
|
4
|
Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.
|
Arch Neurol
|
2007
|
10.75
|
|
5
|
Brain work and brain imaging.
|
Annu Rev Neurosci
|
2006
|
6.99
|
|
6
|
Use of florbetapir-PET for imaging beta-amyloid pathology.
|
JAMA
|
2011
|
6.92
|
|
7
|
APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.
|
Ann Neurol
|
2010
|
6.17
|
|
8
|
Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease.
|
Arch Neurol
|
2009
|
4.55
|
|
9
|
The default mode network and self-referential processes in depression.
|
Proc Natl Acad Sci U S A
|
2009
|
4.05
|
|
10
|
Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly.
|
Biol Psychiatry
|
2009
|
3.72
|
|
11
|
Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study.
|
Lancet Neurol
|
2012
|
3.66
|
|
12
|
Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition.
|
Arch Neurol
|
2009
|
3.60
|
|
13
|
Resting-state functional MRI in depression unmasks increased connectivity between networks via the dorsal nexus.
|
Proc Natl Acad Sci U S A
|
2010
|
3.42
|
|
14
|
Regional aerobic glycolysis in the human brain.
|
Proc Natl Acad Sci U S A
|
2010
|
3.25
|
|
15
|
APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF Aβ42.
|
J Neurosci
|
2010
|
2.99
|
|
16
|
Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease.
|
EMBO Mol Med
|
2009
|
2.87
|
|
17
|
Amyloid deposition, hypometabolism, and longitudinal cognitive decline.
|
Ann Neurol
|
2012
|
2.84
|
|
18
|
Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.
|
Arch Neurol
|
2011
|
2.81
|
|
19
|
Spatial correlation between brain aerobic glycolysis and amyloid-β (Aβ ) deposition.
|
Proc Natl Acad Sci U S A
|
2010
|
2.80
|
|
20
|
Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake.
|
Arch Neurol
|
2008
|
2.62
|
|
21
|
Altered emotional interference processing in affective and cognitive-control brain circuitry in major depression.
|
Biol Psychiatry
|
2007
|
2.61
|
|
22
|
Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report.
|
Arch Neurol
|
2009
|
2.42
|
|
23
|
Brain volume decline in aging: evidence for a relation between socioeconomic status, preclinical Alzheimer disease, and reserve.
|
Arch Neurol
|
2008
|
2.40
|
|
24
|
Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.
|
Neurology
|
2012
|
2.26
|
|
25
|
Exercise and Alzheimer's disease biomarkers in cognitively normal older adults.
|
Ann Neurol
|
2010
|
2.25
|
|
26
|
In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM.
|
Eur J Nucl Med Mol Imaging
|
2003
|
2.25
|
|
27
|
Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later.
|
Neurology
|
2013
|
2.19
|
|
28
|
Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects.
|
J Nucl Med
|
2012
|
2.16
|
|
29
|
Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report.
|
Int J Radiat Oncol Biol Phys
|
2003
|
2.09
|
|
30
|
Relationship of dementia screening tests with biomarkers of Alzheimer's disease.
|
Brain
|
2010
|
1.80
|
|
31
|
Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging.
|
Alzheimers Dement
|
2013
|
1.77
|
|
32
|
Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans.
|
Proc Natl Acad Sci U S A
|
2011
|
1.67
|
|
33
|
Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid.
|
Ann Neurol
|
2013
|
1.63
|
|
34
|
YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease.
|
Biol Psychiatry
|
2010
|
1.59
|
|
35
|
Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods.
|
J Nucl Med
|
2012
|
1.55
|
|
36
|
Antidepressant treatment normalizes hypoactivity in dorsolateral prefrontal cortex during emotional interference processing in major depression.
|
J Affect Disord
|
2008
|
1.53
|
|
37
|
Exercise Engagement as a Moderator of the Effects of APOE Genotype on Amyloid Deposition.
|
Arch Neurol
|
2012
|
1.52
|
|
38
|
Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease.
|
Ann Neurol
|
2011
|
1.51
|
|
39
|
Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology.
|
Arch Neurol
|
2011
|
1.50
|
|
40
|
Regional white matter hyperintensity burden in automated segmentation distinguishes late-life depressed subjects from comparison subjects matched for vascular risk factors.
|
Am J Psychiatry
|
2008
|
1.50
|
|
41
|
Evaluation of 5-ethynyl-2'-deoxyuridine staining as a sensitive and reliable method for studying cell proliferation in the adult nervous system.
|
Brain Res
|
2010
|
1.50
|
|
42
|
Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease.
|
Neurobiol Aging
|
2012
|
1.49
|
|
43
|
Diffuse microstructural abnormalities of normal-appearing white matter in late life depression: a diffusion tensor imaging study.
|
Biol Psychiatry
|
2009
|
1.46
|
|
44
|
Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals.
|
Neurobiol Aging
|
2012
|
1.43
|
|
45
|
Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data.
|
Ann Neurol
|
2011
|
1.40
|
|
46
|
FDG-PET imaging of pulmonary inflammation in healthy volunteers after airway instillation of endotoxin.
|
J Appl Physiol (1985)
|
2006
|
1.38
|
|
47
|
Regulation of blood flow in activated human brain by cytosolic NADH/NAD+ ratio.
|
Proc Natl Acad Sci U S A
|
2006
|
1.32
|
|
48
|
Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline.
|
Alzheimer Dis Assoc Disord
|
2013
|
1.28
|
|
49
|
A possible substrate for dopamine-related changes in mood and behavior: prefrontal and limbic effects of a D3-preferring dopamine agonist.
|
Proc Natl Acad Sci U S A
|
2002
|
1.22
|
|
50
|
Quantitative analysis of PiB-PET with FreeSurfer ROIs.
|
PLoS One
|
2013
|
1.21
|
|
51
|
Positron emission tomography in limited-stage small-cell lung cancer: a prospective study.
|
J Clin Oncol
|
2004
|
1.21
|
|
52
|
Blast-related brain injury: imaging for clinical and research applications: report of the 2008 st. Louis workshop.
|
J Neurotrauma
|
2009
|
1.20
|
|
53
|
Quantifying pulmonary inflammation in cystic fibrosis with positron emission tomography.
|
Am J Respir Crit Care Med
|
2006
|
1.16
|
|
54
|
Cerebral blood flow changes during vagus nerve stimulation for depression.
|
Psychiatry Res
|
2006
|
1.13
|
|
55
|
Greater loss of 5-HT(2A) receptors in midlife than in late life.
|
Am J Psychiatry
|
2002
|
1.11
|
|
56
|
Comparison of methods to quantitate 18F-FDG uptake with PET during experimental acute lung injury.
|
J Nucl Med
|
2004
|
1.11
|
|
57
|
Human brain glucose metabolism may evolve during activation: findings from a modified FDG PET paradigm.
|
Neuroimage
|
2006
|
1.11
|
|
58
|
[3H]4-(dimethylamino)-N-(4-(4-(2-methoxyphenyl)piperazin-1-yl) butyl)benzamide: a selective radioligand for dopamine D(3) receptors. II. Quantitative analysis of dopamine D(3) and D(2) receptor density ratio in the caudate-putamen.
|
Synapse
|
2010
|
1.07
|
|
59
|
[18F]fluorodeoxyglucose positron emission tomography for lung antiinflammatory response evaluation.
|
Am J Respir Crit Care Med
|
2009
|
1.07
|
|
60
|
[(3)H]4-(Dimethylamino)-N-[4-(4-(2-methoxyphenyl)piperazin- 1-yl)butyl]benzamide, a selective radioligand for dopamine D(3) receptors. I. In vitro characterization.
|
Synapse
|
2009
|
1.05
|
|
61
|
Florbetapir f-18: a histopathologically validated Beta-amyloid positron emission tomography imaging agent.
|
Semin Nucl Med
|
2011
|
1.01
|
|
62
|
Noninvasive estimation of the arterial input function in positron emission tomography imaging of cerebral blood flow.
|
J Cereb Blood Flow Metab
|
2012
|
1.00
|
|
63
|
Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans.
|
Proc Natl Acad Sci U S A
|
2012
|
0.95
|
|
64
|
PET amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to Alzheimer's disease.
|
Alzheimers Res Ther
|
2011
|
0.94
|
|
65
|
Neuropathologic heterogeneity does not impair florbetapir-positron emission tomography postmortem correlates.
|
J Neuropathol Exp Neurol
|
2014
|
0.94
|
|
66
|
Pretreatment cerebral metabolic activity correlates with antidepressant efficacy of vagus nerve stimulation in treatment-resistant major depression: a potential marker for response?
|
J Affect Disord
|
2012
|
0.93
|
|
67
|
Endogenous dopamine (DA) competes with the binding of a radiolabeled D₃ receptor partial agonist in vivo: a positron emission tomography study.
|
Synapse
|
2011
|
0.92
|
|
68
|
Cerebrospinal fluid biomarkers, education, brain volume, and future cognition.
|
Arch Neurol
|
2011
|
0.91
|
|
69
|
Cortical binding of pittsburgh compound B, an endophenotype for genetic studies of Alzheimer's disease.
|
Biol Psychiatry
|
2009
|
0.89
|
|
70
|
Cerebral perfusion response to successful treatment of depression with different serotoninergic agents.
|
J Neuropsychiatry Clin Neurosci
|
2004
|
0.88
|
|
71
|
Brain blood-flow change with acute vagus nerve stimulation in treatment-refractory major depressive disorder.
|
Brain Stimul
|
2011
|
0.88
|
|
72
|
Development of a PET radiotracer for non-invasive imaging of the reactive oxygen species, superoxide, in vivo.
|
Org Biomol Chem
|
2014
|
0.87
|
|
73
|
Quantification of 18F-florbetapir PET: comparison of two analysis methods.
|
Eur J Nucl Med Mol Imaging
|
2015
|
0.85
|
|
74
|
Quantitation of pulmonary transgene expression with PET imaging.
|
J Nucl Med
|
2004
|
0.82
|
|
75
|
PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders.
|
BMC Neurol
|
2014
|
0.82
|
|
76
|
Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
|
Int J Geriatr Psychiatry
|
2014
|
0.81
|
|
77
|
Decreased hippocampal 5-HT(2A) receptor binding in older depressed patients using [18F]altanserin positron emission tomography.
|
Neuropsychopharmacology
|
2004
|
0.80
|
|
78
|
Radiation dosimetry of florbetapir F 18.
|
EJNMMI Res
|
2014
|
0.79
|
|
79
|
Effect of Amyloid Imaging on the Diagnosis and Management of Patients with Cognitive Decline: Impact of Appropriate Use Criteria.
|
Dement Geriatr Cogn Disord
|
2016
|
0.79
|
|
80
|
Association of cerebral metabolic activity changes with vagus nerve stimulation antidepressant response in treatment-resistant depression.
|
Brain Stimul
|
2013
|
0.78
|
|
81
|
Antidepressant efficacy of olanzapine as monotherapy in major depressive disorder, without psychosis: a pilot study.
|
Psychiatry Res
|
2006
|
0.75
|
|
82
|
Effectiveness of Florbetapir PET Imaging in Changing Patient Management.
|
Dement Geriatr Cogn Disord
|
2017
|
0.75
|